SCHEMBL183340

SCHEMBL183340

CSc1ccc(O[C]=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 4/20 0.44
CYP1A2 P05177 4/20 0.44
CYP1B1 Q16678 4/20 0.44
ALDH1A1 P00352 6/20 0.41
PLK1 P53350 1/20 0.36
LMNA P02545 4/20 0.36
MAPT P10636 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTT P42858 1/20 0.36
SLC6A4 P31645 2/20 0.35
MAOB P27338 1/20 0.35
AOC3 Q16853 1/20 0.35
HTR2A P28223 1/20 0.35
KCNH2 Q12809 1/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
JAK2 O60674 1/20 0.34
TSHR P16473 1/20 0.34
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8142070 0.80 CA2 (0.32)
SCHEMBL17042403 0.77 CYP1A1 (0.44) CYP1A1CYP1A2CYP1B1ALDH1A1LMNA
SCHEMBL194155 0.74 MAOA (0.45) ALDH1A1LMNAMAPTSLC6A4MAOB
SCHEMBL96667 0.73 CA1 (0.58) ALDH1A1MAPTNPSR1GAAKDM4E
SCHEMBL95901 0.73 ACHE (0.48) CYP1A2ALDH1A1LMNAMAPTHTT
SCHEMBL15908415 0.73 CYP1A1 (0.44) CYP1A1CYP1A2CYP1B1ALDH1A1PLK1
SCHEMBL6214043 0.72 MAPT (0.43) CYP1A1CYP1A2CYP1B1ALDH1A1LMNA
SCHEMBL2774995 0.72 CYP1A1 (0.52) CYP1A1CYP1A2CYP1B1ALDH1A1SLC6A4
SCHEMBL9123387 0.71
SCHEMBL83839 0.71 ALDH1A1 (0.58) CYP1A1CYP1A2CYP1B1ALDH1A1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3053944-B1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR SHINETSU CHEMICAL CO (JP) 2021-10-06 EP claimed
JP-2007501805-A 2007-02-01 JP claimed
EP-1651638-A1 PYRIDYL PIPERAZINYL UREAS JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-03 EP claimed
US-6888001-B2 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. LEE JUNG S (US) 2005-05-03 US claimed
US-20050049241-A1 Pyridyl piperazinyl ureas JANSSEN PHARMACEUTICA, N.V. (BE) 2005-03-03 US claimed
WO-2005014580-A1 PYRIDYL PIPERAZINYL UREAS JANSSEN PHARMACEUTICA, N.V. (BE) 2005-02-17 WO claimed
EP-1107965-B1 PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION ORTHO MCNEIL PHARM INC (US) 2004-08-11 EP claimed
US-20030207858-A1 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. LEE JUNG S (US) 2003-11-06 US claimed
US-6562847-B1 Useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-05-13 US claimed
EP-1107965-A1 PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION Ortho-McNeil Pharmaceutical, Inc. (US) 2001-06-20 EP claimed
WO-2000010997-A1 PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-03-02 WO claimed
US-20230114064-A1 NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-04-13 US disclosed
EP-3042934-B1 COLORED COMPOSITION, CURED FILM, COLOR FILTER, COLOR-FILTER MANUFACTURING METHOD, SOLID-STATE IMAGING ELEMENT, IMAGE DISPLAY DEVICE, POLYMER, AND XANTHENE DYE FUJIFILM CORP (JP) 2022-11-09 EP disclosed
EP-3053944-B1 METHOD FOR PRODUCING POLYALKYLENE GLYCOL DERIVATIVE HAVING AMINO GROUP AT END, POLYMERIZATION INITIATOR FOR USE IN THE SAME, AND ALCOHOL COMPOUND AS RAW MATERIAL FOR THE POLYMERIZATION INITIATOR SHINETSU CHEMICAL CO (JP) 2021-10-06 EP disclosed
US-11066430-B2 Method for producing polyalkylene glycol derivative having amino group at end SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-07-20 US disclosed
EP-1160236-A2 Production of mixed acid anhydride and amine compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-12-05 EP disclosed
EP-1107965-A1 PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION Ortho-McNeil Pharmaceutical, Inc. (US) 2001-06-20 EP disclosed
WO-2000010997-A1 PYRIDYL ETHERS AND THIOETHERS AS LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTOR AND ITS THERAPEUTIC APPLICATION ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-03-02 WO disclosed
US-5942381-A DEVELOPMENT INHIBITOR RELEASING COUPLER; MAGENTA EASTMAN KODAK COMPANY (US) 1999-08-24 US disclosed
EP-0884639-A1 Photographic element and process employing active, stable benzotriazole-releasing DIR couplers EASTMAN KODAK COMPANY (US) 1998-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066430-B2 Method for producing polyalkylene glycol derivative having amino group at end RAD1, AP3B1, RER1 CYP1A1 478/4885CYP1A2 618/4885CYP1B1 281/4885
US-20230114064-A1 NOVEL HETEROAROMATIC SILICON-FLUORIDE-ACCEPTORS USEFUL FOR 18F LABELING OF MOLECULES AND BIOMOLECULES, AND METHODS OF PREPARING SAME KIT, FER, FUT8 CYP1A1 3048/4885CYP1A2 4204/4885CYP1B1 2792/4885
US-20050049241-A1 Pyridyl piperazinyl ureas VIPR1, UTS2R, GPR17 CYP1A1 730/4885CYP1A2 2043/4885CYP1B1 1356/4885
US-20030207858-A1 Selective modulators of the nicotinic acetylcholine receptor useful in the treatment of pain, Alzheimer's disease, memory loss or dementia or loss of motor function. CHRM1, CHRM5, CHRM2 CYP1A1 1141/4885CYP1A2 1309/4885CYP1B1 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.